Vermillion Announces Recognition by and Publication in Two Top Physician Educational Resources
Article highlighting OVA1’s biomarker test published in the March 2018 issue of “UpToDate,” an evidence-based physician-authored publication
OVA1 now included as part of a national Continuing Medical Education (CME) program
AUSTIN, Texas, April 25, 2018 — ASPiRA LABs, a Vermillion company (NASDAQ: VRML), today announced that two top physician educational resources, UpToDate and the National Continuing Medical Education (CME) Program, have recognized the OVA1 test for its risk assessment outcomes.
“Support from either one of these renowned resources would have been meaningful, but having the combination of the support will allow us to build awareness and adoption of OVA1 even more quickly,” stated Valerie Palmieri, President and CEO of Vermillion. “We are on a mission to make sure every physician is aware of OVA1. Every day, 39 women die of ovarian cancer. Since launching OVA1, we have made a difference in the lives of over 103,000 patients with zero safety or efficacy issues. OVA1 is FDA cleared, endorsed by the American Congress of Obstetricians and Gynecologists (ACOG), and covered by Medicare nationwide, and Medicaid on a state-by-state basis. Our goal is to change the standard of care for managing both high-risk and low-risk pelvic mass patients, as 1 in 5 women have a pelvic mass in their lifetime. We have built a solid foundation and look forward to executing on our plan.”
In the UpToDate article entitled: “Serum biomarkers for evaluation of an adnexal mass for epithelial carcinoma of the ovary, fallopian tube, or peritoneum,” published in the March 2018 issue, authors Frederick Rand Ueland, MD and Andrew John Li, MD found that physicians using the OVA1 test in conjunction with the American College of Obstetricians and Gynecologists (ACOG) criteria identified more ovarian cancers than physicians using the ACOG criteria alone. UpToDate is an evidence-based physician-authored clinical decision support resource used by physicians to make point-of-care decisions and is read by over 1.3 million clinicians in more over 180 countries.
In a national Continuing Medical Education (CME) program, OVA1 is included as a risk assessment strategy in an activity entitled: “Adnexal Mass Management: Risk Stratification & Management Practice for Best Patient Outcomes.”
The CME program is available through Omnia Education’s website for CME credit
About Vermillion, Inc.
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, Inc.’s tests are intended to characterize and stage disease, and to help guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, to perform additional testing, or to assist in monitoring response to therapy.
Forward Looking Statements
This press release contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding Vermillion’s expectations about the closing of the offerings and use of net proceeds therefrom. Words such as “may,” “expects,” “intends,” “anticipates,” “believes,” “estimates,” “plans,” “seeks,” “could,” “should,” “continue,” “will,” “potential,” “projects” and similar expressions are intended to identify forward-looking statements. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including the risks and uncertainties associated with market conditions and the completion of the proposed offerings, as well as risks and uncertainties inherent in Vermillion’s business, including those described in the section entitled “Risk Factors” in Vermillion’s Annual Report on Form 10-K for the year ended December 31, 2017 and in Vermillion’s other periodic filings with the SEC. The events and circumstances reflected in Vermillion’s forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Vermillion expressly disclaims any obligation to update, amend or clarify any forward-looking statements to reflect events, new information or circumstances occurring after the date of this press release, except as required by law.
Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC